India's DCGI Orders Denmark's Lundbeck To Prove Efficacy Of Deanxit
This article was originally published in PharmAsia News
Executive Summary
India's drug regulator has given Denmark's Lundbeck up to six months to prove the efficacy of its Deanxit (flupentixol/melitracen) anti-depressant long after questions had been raised about the drug.